[1]曹星月 武晓泓.基因拷贝数异常在甲状腺癌诊断和预后判断中的 应用进展[J].国际内分泌代谢杂志,2019,39(01):29-33.[doi:10.3760/cma.j.issn.1673-4157.2019.01.007]
 Cao Xingyue,Wu Xiaohong.Progress in the application of gene copy number variations in diagnosis and prognosis of thyroid cancer[J].International Journal of Endocrinology and Metabolism,2019,39(01):29-33.[doi:10.3760/cma.j.issn.1673-4157.2019.01.007]
点击复制

基因拷贝数异常在甲状腺癌诊断和预后判断中的 应用进展()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
39
期数:
2019年01期
页码:
29-33
栏目:
综述
出版日期:
2019-01-20

文章信息/Info

Title:
Progress in the application of gene copy number variations in diagnosis and prognosis of thyroid cancer
作者:
曹星月 武晓泓
南京医科大学第一附属医院内分泌科 210029
Author(s):
Cao Xingyue Wu Xiaohong
Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
关键词:
甲状腺癌 基因拷贝数异常 分子标志物
Keywords:
Thyroid carcinoma Gene copy number variations Molecular marker
DOI:
10.3760/cma.j.issn.1673-4157.2019.01.007
摘要:
拷贝数异常(CNVs)是广泛存在于人体基因组的一种结构变异现象。异常片段大小从几十个碱基(>50 bp)到数Mb范围不等,主要包括拷贝数的扩增、删除、缺失、插入、重组以及多位点的复杂变异。相关研究发现,12号染色体扩增现象仅存在于甲状腺腺瘤(FA),而22号染色体缺失常见于FA和滤泡型乳头状癌(FVPTC),且并未在良性结节中发现其缺失现象。更有学者根据CNVs的类型将甲状腺癌分为4大类,揭示不同类型CNVs对甲状腺癌预后的影响。
Abstract:
Copy number variations(CNVs)is a structural variation widely existed in human genome. The size of the abnormal fragment ranges from dozens of bases(>50 bp)to several Mb, mainly including the amplification, deletion, loss, insertion, recombination and complex variation of multiple sites. Amplification of chromosome 12 was found only in thyroid adenomas(FA), whereas deletion of chromosome 22 was common in FA and follicular papillary carcinoma(FVPTC), and no deletion of chromosome 22 was found in benign nodules. According to the types of CNVs, thyroid carcinoma is divided into four categories, revealing the impact of different types of CNVs on the prognosis of thyroid carcinoma.

参考文献/References:

[1] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.DOI:10.3322/caac.21338.
[2] Valderrabano P,McIver B.Evaluation and management of indeterminate thyroid nodules: the revolution of risk stratification beyond cytological diagnosis[J]. Cancer Control,2017,24(5):1073274817729231.DOI:10.1177/1073274817729231.
[3] Decaussin-Petrucci M,Descotes F,Depaepe L,et al. Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy[J].Cytopathology,2017,28(6):482-487.DOI:10.1111/cyt.12493.
[4] Insilla AC,Proietti A,Borrelli N,et al.TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases[J].Oncol Lett,2018,15(3):2763-2770.DOI:10.3892/ol.2017.7675.
[5] Dolatabadian A,Patel DA,Edwards D,et al.Copy number variation and disease resistance in plants[J].Theor Appl Genet,2017,130(12):2479-2490.DOI:10.1007/s00122-017-2993-2.
[6] Richardson SR,Doucet AJ,Kopera HC,et al.The influence of LINE-1 and SINE retrotransposons on mammalian genomes[J].Microbiol Spectr,2015,3(2):MDNA3-0061-2014.DOI:10.1128/microbiolspec.MDNA3-0061-2014.
[7] Park TJ,Hwang MY,Moon S,et al.Identification of a copy number variation on chromosome 20q13.12 associated with osteoporotic fractures in the Korean population[J].Genomics Inform,2016,14(4):216-221.DOI:10.5808/GI.2016.14.4.216.
[8] Shaikh TH.Copy number variation disorders[J].Curr Genet Med Rep,2017,5(4):183-190.DOI:10.1007/s40142-017-0129-2.
[9] VanderWeele DJ,Finney R,Katayama K,et al.Genomic heterogeneity within individual prostate cancer foci impacts predictive biomarkers of targeted therapy[J].Eur Urol Focus,2018,pii:S2405-S4569(18)30007-5.DOI:10.1016/j.euf.2018.01.006.
[10] Schumacher SE,Shim BY,Corso G,et al.Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients[J].PLoS One,2017,12(4):e0176045. DOI:10.1371/journal.pone.0176045.
[11] Woo HG,Choi JH,Yoon S,et al.Integrative analysis of genomic and epigenomic regulation of the transcriptome in liver cancer[J].Nat Commun,2017,8(1):839.DOI:10.1038/s41467-017-00991-w.
[12] Kaveh F,Baumbusch LO,Nebdal D,et al.A systematic comparison of copy number alterations in four types of female cancer[J].BMC Cancer,2016,16(1):913.DOI:10.1186/s12885-016-2899-4.
[13] Liu S,Song L,Cram DS,et al.Traditional karyotyping vs copy number variation sequencing for detection of chromosomalabnormalities associated with spontaneous miscarriage[J].Ultrasound Obstet Gynecol,2015,46(4):472-477.DOI:10.1002/uog.14849.
[14] Hollox EJ.Analysis of copy number variation using the paralogue ratio test(PRT)[J].Methods Mol Biol,2017,1492:127-146.DOI:10.1007/978-1-4939-6442-0_8.
[15] Reiner J,Karger L,Cohen N,et al.Chromosomal microarray detection of constitutional copy number variation using saliva DNA[J].J Mol Diagn,2017,19(3):397-403.DOI:10.1016/j.jmoldx.2016.11.006.
[16] Ko JM.Chromosomal microarray: application for congenital heart diseases[J].Korean Circ J,2018,48(3):233-235.DOI:10.4070/kcj.2018.0032.
[17] López S,García I,Smith I,et al.Discovery of copy number variants by multiplex amplifiable probe hybridization(MAPH)in candidate pigmentation genes[J].Ann Hum Biol,2015,42(5):485-493.DOI:10.3109/03014460.2014.965202.
[18] Marcinkowska-Swojak M,Uszczynska B,Figlerowicz M,et al.An MLPA-based strategy for discrete CNV genotyping: CNV-miRNAs as an example[J].Hum Mutat,2013,34(5):763-773.DOI:10.1002/humu.22288.
[19] Fukami M,Miyado M.Next generation sequencing and array-based comparative genomic hybridization for molecular diagnosis of pediatric endocrine disorders[J].Ann Pediatr Endocrinol Metab,2017,22(2):90-94.DOI:10.6065/apem.2017.22.2.90.
[20] Pirooznia M,Goes FS,Zandi PP.Whole-genome CNV analysis:advances in computational approaches[J].Front Genet,2015,6:138.DOI:10.3389/fgene.2015.00138.
[21] Da Silva L,James D,Simpson PT,et al.Tumor heterogeneity in a follicular carcinoma of thyroid: a study by comparative genomic hybridization[J].Endocr Pathol,2011,22(2):103-107.DOI:10.1007/s12022-011-9154-y.
[22] Liu Y,Cope L,Sun W,et al.DNA copy number variations characterize benign and malignant thyroid tumors[J].J Clin Endocrinol Metab,2013,98(3):E558-E566.DOI:10.1210/jc.2012-3113.
[23] Hess J,Thomas G,Braselmann H,et al.Gain of chromosome band 7q11 in papillary thyroid carcinomas of young patients is associated with exposure to low-dose irradiation[J].Proc Natl Acad Sci U S A,2011,108(23):9595-9600.DOI:10.1073/pnas.1017137108.
[24] Ye L,Zhou X,Huang F,et al.The genetic landscape of benign thyroid nodules revealed by whole exome and transcriptome sequencing[J].Nat Commun,2017,8:15533. DOI:10.1038/ncomms15533.
[25] Cancer Genome Atlas Research Network.Integrated genomic characterization of papillary thyroid carcinoma[J].Cell,2014,159(3):676-690.DOI:10.1016/j.cell.2014.09.050.
[26] Yoo SK,Lee S,Kim SJ,et al.Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers[J].PLoS Genet,2016,12(8):e1006239.DOI:10.1371/journal.pgen.1006239.
[27] Passon N,Bregant E,Sponziello M,et al.Somatic amplifications and deletions in genome of papillary thyroid carcinomas[J].Endocrine,2015,50(2):453-464.DOI:10.1007/s12020-015-0592-z.
[28] Ciampi R,Romei C,Cosci B,et al.Chromosome 10 and RET gene copy number alterations in hereditary and sporadic medullary thyroid carcinoma[J].Mol Cell Endocrinol,2012,348(1):176-182.DOI:10.1016/j.mce.2011.08.004.
[29] Liang J,Cai W,Feng D,et al.Genetic landscape of papillary thyroid carcinoma in the Chinese population[J].J Pathol,2018,244(2):215-226.DOI:10.1002/path.5005.
[30] Matsuse M,Sasaki K,Nishihara E,et al.Copy number alteration and uniparental disomy analysis categorizes Japanese papillary thyroid carcinomas into distinct groups[J].PLoS One,2012,7(4):e36063.DOI:10.1371/journal.pone.0036063.
[31] Zitzelsberger H,Unger K.DNA copy number alterations in radiation-induced thyroid cancer[J].Clin Oncol(R Coll Radiol),2011,23(4):289-296.DOI:10.1016/j.clon.2011.01.154.
[32] Kurelac I,de Biase D,Calabrese C,et al.High-resolution genomic profiling of thyroid lesions uncovers preferential copy numbergains affecting mitochondrial biogenesis loci in the oncocytic variants[J].Am J Cancer Res,2015,5(6):1954-1971.
[33] Duquette M,Sadow PM,Husain A,et al.Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model[J].Oncotarget,2015,6(40):42445-42467.DOI:10.18632/oncotarget.6442.
[34] Wang N,Kjellin H,Sofiadis A,et al.Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma[J].Oncotarget,2016,7(16):21332-21346.DOI:10.18632/oncotarget.7237.
[35] Grubbs EG,Williams MD,Scheet P,et al.Role of CDKN2C copy number in sporadic medullary thyroid carcinoma[J].Thyroid,2016,26(11):1553-1562.DOI:10.1089/thy.2016.0224.

相似文献/References:

[1]张蓉,俞立波,李连喜.组蛋白修饰与甲状腺癌[J].国际内分泌代谢杂志,2014,(05):348.[doi:10.3760/cma.j.issn.1673-4157.2014.05.017]
 Zhang Rong,Yu Libo,Li Lianxi..Histone modification and thyroid tumor[J].International Journal of Endocrinology and Metabolism,2014,(01):348.[doi:10.3760/cma.j.issn.1673-4157.2014.05.017]
[2]李兴佳,徐书杭,刘超.雌激素及其受体与甲状腺癌的关系[J].国际内分泌代谢杂志,2016,36(04):273.[doi:10.3760/cma.j.issn.1673-4157.2016.04.15]
 Li Xingjia,Xu Shuhang,Liu Chao.Relationship between estrogen, its receptors and thyroid cancer[J].International Journal of Endocrinology and Metabolism,2016,36(01):273.[doi:10.3760/cma.j.issn.1673-4157.2016.04.15]
[3]郑仁东,刘超.白细胞介素-6与甲状腺疾病[J].国际内分泌代谢杂志,2016,36(05):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
 Zheng Rendong,Liu Chao.Interleukin-6 and thyroid disease[J].International Journal of Endocrinology and Metabolism,2016,36(01):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
[4]郑仁东,刘超.STAT3与甲状腺肿瘤[J].国际内分泌代谢杂志,2017,37(05):345.
 Zheng Rendong,Liu Chao..STAT3 and thyroid tumor[J].International Journal of Endocrinology and Metabolism,2017,37(01):345.
[5]孟祥慧 徐书杭 陈国芳 刘超.二甲双胍在甲状腺癌防治中的作用[J].国际内分泌代谢杂志,2018,38(04):237.[doi:10.3760/cma.j.issn.1673-4157.2018.04.005]
 Meng Xianghui*,Xu Shuhang,Chen Guofang,et al.Role of metformin in prevention and treatment of thyroid cancer[J].International Journal of Endocrinology and Metabolism,2018,38(01):237.[doi:10.3760/cma.j.issn.1673-4157.2018.04.005]
[6]张会峰 胡天赤 陈学勤 叶向荣 刘超.丙型肝炎病毒感染与自身免疫性甲状腺疾病 及甲状腺癌风险[J].国际内分泌代谢杂志,2019,39(02):128.[doi:10.3760/cma.j.issn.1673-4157.2019.02.014]
 Zhang Huifeng,Hu Tianchi,Chen Xueqin,et al.Relationship between hepatitis C virus infection and the risk of autoimmune thyroid diseases and thyroid cancer[J].International Journal of Endocrinology and Metabolism,2019,39(01):128.[doi:10.3760/cma.j.issn.1673-4157.2019.02.014]
[7]张玉洁 孟召伟 章明放 宋丽丽 李宁.甲状腺疾病的代谢组学研究现状[J].国际内分泌代谢杂志,2019,39(03):173.[doi:10.3760/cma.j.issn.1673-4157.2019.03.007]
 Zhang Yujie,Meng Zhaowei,Zhang Mingfang,et al.Research status of metabolomics in thyroid diseases[J].International Journal of Endocrinology and Metabolism,2019,39(01):173.[doi:10.3760/cma.j.issn.1673-4157.2019.03.007]
[8]田勍,洪天配.甲状腺结节诊治过程中的难点与应对[J].国际内分泌代谢杂志,2021,41(06):557.[doi:10.3760/cma.j.cn121383-20210727-07074]
 Tian Qing,Hong Tianpei..Difficulties and countermeasures in the diagnosis and treatment of thyroid nodules[J].International Journal of Endocrinology and Metabolism,2021,41(01):557.[doi:10.3760/cma.j.cn121383-20210727-07074]
[9]张雅,相萍萍,徐书杭,等.经皮无水乙醇注射治疗甲状腺结节:老方法的新认识[J].国际内分泌代谢杂志,2022,42(06):469.[doi:10.3760/cma.j.cn121383-20210926-09075]
 Zhang Ya,Xiang Pingping,Xu Shuhang,et al.Percutaneous ethanol ablation for thyroid nodules: new perspectives on an old paradigm[J].International Journal of Endocrinology and Metabolism,2022,42(01):469.[doi:10.3760/cma.j.cn121383-20210926-09075]

备注/Memo

备注/Memo:
通信作者:武晓泓,Email:drxhwu@njmu.edu.cn
Corresponding author: Wu Xiaohong, Email: drxhwu@njmu.edu.cn
更新日期/Last Update: 2019-01-20